Drugs / SMP-3124
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06526819 | Aug 2024 → Dec 2028 expected | cancer | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMP-3124 | “Liposomal encapsulation formulation of SMP-3124” NCT06526819 ↗ |
| Route | Intravenous | “SMP-3124LP continuous IV infusion every 2 weeks (q2w)” NCT06526819 ↗ |